Cardan Capital Partners’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Cardan Capital Partners’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-15,177	Closed	-$353K	–	169
2018 Q4	$353K	Buy	15,177 +2,057	+16%	+$56.1K	0.06%	127
2018 Q3	$453K	Buy	+13,120	New	+$443K	0.07%	132
2017 Q4	–	Sell	-23,541	Closed	-$686K	–	125
2017 Q3	$686K	Buy	23,541 +635	+3%	+$16.4K	0.14%	75
2017 Q2	$550K	Buy	22,906 +1,895	+9%	+$42.4K	0.11%	78
2017 Q1	$487K	Buy	21,011 +2,428	+13%	+$51.6K	0.1%	81
2016 Q4	$342K	Buy	18,583 +6,909	+59%	+$138K	0.08%	87
2016 Q3	$264K	Buy	+11,674	New	+$239K	0.06%	93

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AWCI

Alpine Woods Capital Investors Purchase, New York $417M AUM 26.83% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cardan Capital Partners's BBC Position: Q1 2019 in Review

Cardan Capital Partners sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2019, closing a stake of 15,177 shares — an estimated $353K sold.

Cardan Capital Partners first reported a position in BBC in Q3 2016 and held it in 7 quarters. The position peaked at $686K in Q3 2017. 15 funds tracked by Wall St. Rank hold BBC as of Q1 2019.

Cardan Capital Partners reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2019 after selling out during the quarter.
Cardan Capital Partners sold 15,177 Virtus Biotech Clinical Trials ETF shares in Q1 2019, an estimated $353K.
Cardan Capital Partners first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2016 and held it in 7 quarters.
Cardan Capital Partners's Virtus Biotech Clinical Trials ETF position peaked at $686K in Q3 2017.
15 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2019.

Based on Cardan Capital Partners's 13F filing for Q1 2019, filed 9 Apr 2019.